Peters M, et al. - Researchers analyzed changes in epidermal growth factor receptor (EGFR) mutation testing and treatment practices in non-small-cell lung cancer via two surveys conducted 18 months apart. They performed the first survey between December 2014 and January 2015 in Canada, France, Germany, Italy, Japan, South Korea, Spain, Taiwan, the UK, and the US; the second survey between July and August 2016 in the same countries, plus China. They excluded China from year-on-year comparisons. A total of 562 physicians were included in the first survey and 707 in the second. In 80% of cases globally, (excluding China; 2015: 81%), prior to initiation of first-line therapy, EGFR mutation testing was requested by physicians. A large proportion of patients did not receive tyrosine kinase inhibitor treatment on the basis of mutation status due to incomplete implementation of guidelines, despite the observed improvements in the availability of test results before first-line therapy. Tumor histology, insufficient tissue, poor performance status, and long test turnaround time accounted for non-testing, as observed year-on-year. If treatment parity for eligible patients is to be achieved, it is necessary to address receiving timely results. For achieving improved results, main steps are physician education and closer guideline concordance.